Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML

Bone Marrow Transplantation

Volumn 32, Issue 3, 2003, Pages 237-242

  Bonifazi, F ^a   Bandini, G ^a   Rondelli, D ^a,b   Falcioni, S ^a   Stanzani, M ^a   Bontadini, A ^a   Tazzari, P L ^a   Arpinati, M ^a   Giannini, B ^a   Conte, R ^a   Baccarani, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ATG; CML; GVHD; Unrelated transplatation

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; IMATINIB; METHOTREXATE; THYMOCYTE ANTIBODY;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEADACHE; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RASH; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMAN; INCIDENCE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RABBITS; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 10744229854     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704138     Document Type: Article

References (37)

1. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
2. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in good risk chronic granulocytic leukemia. Blood 1984; 63: 789-799.
3. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850-858.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541-1548.
5. Bonifazi F, De Vivo A, Rosti G et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 2001; 98: 3074-3081.
6. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia developed for the American Society of Hematology. Blood 1999; 94: 1517-1536.
7. Kantarjian HM, Cortes JE, O'Brien S et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101: 97-100.
8. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
9. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
10. McGlave P, Ou Shu X, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 2000; 95: 2219-2225.
11. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematological malignancies using molecular typing for donor selection and graft versus host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228-1234.
12. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic bone marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
13. Horstmann M, Stockschlader M, Kruger W et al. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol 1995; 71: 77-81.
14. Kroger N, Zabelina T, Kruger W et al. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001; 80: 209-215.
15. Remberger M, Svahn B-M, Hentschke P et al. Effect on cytokine release and graft versus host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823-830.
16. Holler E, Ledderose G, Knabe H et al. Serotherapy during pretransplant conditioning in unrelated donor BMT: dose dependent modulation of GvHD. Bone Marrow Transplant 1998; 27 (Suppl. 1): 105.
17. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194-1200.
18. Browning MJ, Krausa P, Rowan A et al. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA 1993; 90: 2842-2845.
19. Hein J, Bottcher K, Grundmann R et al. Low resolution DNA typing of the HLA-B5 cross-reactive group by nested PCR-SSP. Tissue Antigens 1995; 45: 27.
20. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
21. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
22. Radich JP, Gooley T, Bryant E et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients 'late,' 18 months or more after transplantation. Blood 2001; 98: 1701-1707.
23. Lin F, van Rhee F, Goldman JM, Cross NCP. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87: 4473-4478.
24. Martinelli G, Montefusco V, Testoni N et al. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000; 85: 653-658.
25. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
27. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc (B) 1972; 34: 354-360.
28. Ferrara GB, Bacigalupo A, Lamparelli T et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood 2001; 98: 3150-3155.
29. Laughlin MJ, Barker J, Bambach B et al. Hematopoietic engraftment and survival in adult recipients of umbilicalcord blood from unrelated donors. N Engl J Med 2001; 344: 1815-1821.
30. Eiermann TH, Lambrecht P, Zander AR. Monitoring antithymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999; 23: 779-781.
31. Krenger W, Ferrara JL. Graft-versus-host-disease and the Th1/Th2 paradigm. Immunol Res 1996; 15: 50-73.
32. Pistillo MP, Tazzari PL, Bonifazi F et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. Transplantation 2002; 73: 1295-1302.
33. Zander AR, Zabelina T, Kroger N et al. Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999; 23: 889-893.
34. Finke J, Bertz H, Schmoor C et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303-313.
35. Ringden O, Remberger M, Carlens S et al. Low incidence of acute graft versus host disease using unrelated HLA-A, HLA-B and HLA-DR-compatible donors and conditioning including anti-T-cell antibodies. Transplantation 1998; 66: 620-625.
36. Slavin S, Nagler A, Naparsteck E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
37. Bacigalupo A, Lamparelli T, Guidi S et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.